AstraZeneca's Brilinta OK'd in U.S. for reducing stroke

• The FDA approves AstraZeneca's (NASDAQ:AZN) Brilinta (ticagrelor) to reduce the risk of stroke in patients with acute ischemic stroke or high-risk transient ischemic attack.
• The blood thinner was first approved in the U.S. in July 2011 for acute coronary syndrome.
• https://seekingalpha.com/news/3633029-astrazenecas-brilinta-okd-in-u-s-for-reducing-stroke